Organigram gets Nasdaq bid-price notice, May 2027 deadline

Organigram has until May 2027 to cure a Nasdaq bid-price deficiency

Nasdaq issued Organigram a bid-price deficiency notice, and the company has a deadline in May 2027 to regain compliance, according to Mugglehead Investment Magazine.

Nasdaq's minimum bid rule generally requires a closing price of at least $1.00 per share. A notice means the stock traded below that threshold for a sustained stretch. The listing isn't gone. It's on watch.

The signal available to CannIntel doesn't include the notice text, the specific date it was issued, or the share price that triggered it, and we aren't filling those gaps with guesses. Organigram's own filing and press release are the documents to check.

A notice is a warning, not a delisting

Under Nasdaq's standard process, a company that receives a bid-price notice gets a compliance window, and a deadline in May 2027 signals the company has a long runway.

The cleanest read on this notice is that it creates a management problem, not a market event. Nothing changes for trading today. Organigram stays listed while the clock runs.

Companies in this spot typically have two paths: the stock recovers on its own, or management pursues a reverse share split to lift the nominal price. Neither is confirmed here. CannIntel has no verified statement from Organigram on its intended approach.

Why the notice matters for Canadian LPs

The notice adds to a pattern of listing-compliance pressure on cannabis producers whose shares have been ground down by years of price compression.

Canadian licensed producers face thin margins, oversupply, and a market that has rewarded few of them. A Nasdaq listing gives a Canadian LP access to U.S. institutional investors who can't touch plant-touching names on domestic exchanges. Losing it would shrink that pool.

That's the real stake. A delisting wouldn't change the operating business in Canada, but it would narrow the investor base and raise the cost of capital.

What shareholders should watch

The decision point is whether Organigram pursues a reverse split or relies on organic price recovery before May 2027.

A reverse split fixes the optics fast. It also often signals weakness and can pressure the stock afterward. Shareholder approval requirements and any Canadian corporate-law steps would shape the timeline, and those details sit in Organigram's filings, not in the signal we have.

Watch, too, for a second notice or any request for an extension. Nasdaq rules allow additional compliance periods in some cases, but that depends on the listing tier and the company meeting other conditions.

The broader compliance backdrop

Organigram joins a growing list of cannabis names managing exchange-compliance clocks while sector sentiment stays weak.

For full background on this story, see the CannIntel topic hub on Organigram Nasdaq compliance. Canada's Health Canada-licensed producers and U.S. exchanges have been on a collision course with low share prices for years.

The notice is routine in process and meaningful in signal. A May 2027 deadline buys time. It doesn't buy a fix.

The next signal: Organigram's own disclosure of its compliance plan, and any shareholder-meeting notice that mentions a share consolidation.